Pfizer And Lilly Preparing To Resume Phase 3 Chronic Pain Program For Tanezumab – March 23, 2015
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) announced today that they are preparing to resume the Phase 3 clinical program for tanezumab.
In the prior clinical studies of more than 11,000 patients, tanezumab demonstrated clinically meaningful efficacy vs. placebo and other select commonly used pain medicines.
I wonder what other “select commonly used pain medicines” it was tested against, when “commonly used” includes everything from aspirin and Tylenol to oxycodone. Continue reading
Complications of Uncontrolled, Persistent Pain – By Forest Tennant, MD, DrPH – Jan 2018
To the unfortunate patient who is afflicted and the practitioner who treats it, incurable, persistent pain is truly its own disease regardless of its underlying cause.
Persistent pain, which is also often characterized as chronic or intractable, has all the ramifications of a disease in that it may have pre-clinical and overt phases.
I like that he calls it “persistent pain” instead of “chronic pain”, a term which has become synonymous in the public’s eye as a whining, complaining, catastrophizing, gonna-be addict. Continue reading
Opioid Addicts Turning to Unapproved Antidepressant – By Dennis Thompson – Aug 2018
It looks like people are trying whatever drugs they can find to ease their misery in the United States these days, while the prohibitionists are trying to make them unavailable as soon as people find “unauthorized” relief from them.
In a trend that suggests opioid addicts are turning to new fixes, a government report shows that the use of an unapproved antidepressant is becoming more widespread in the United States.
Tianeptine is used in some European, Asian and Latin American countries for treatment of depression and anxiety. But the U.S. Food and Drug Administration has not approved use of the drug in the United States. Continue reading
Americans do not take more pills than Europeans – New York Times – By Austin Frakt – Nov. 12, 2018
I found this article an excellent explanation of how drug prices got so high here when they’re so much cheaper in other countries:
There was a time when America approximated other wealthy countries in drug spending. But in the late 1990s, U.S. spending took off. It tripled between 1997 and 2007, according to a study in Health Affairs.
Then a slowdown lasted until about 2013, before spending shot up again. What explains these trends?
By 2015, American annual spending on prescription drugs reached about $1,000 per person and 16.7 percent of overall personal health care spending. Continue reading
Are Anticonvulsants Effective for Low Back Pain? – MPR – Diana Ernst, RPh – July 2018
Here’s another review showing that anticonvulsants (anti-epileptics like Lyrica and gabapentin) are not effective for pain, even though they are increasingly prescribed for it.
For no other purpose than to avoid using opioids, pain patients are being prescribed all kinds of drugs off-label because they may be effective for some kinds of pain is some people some of the time.
Pain management doctors are forced to practice medicine based on hope, not evidence, when the most effective drugs for this condition are prohibited due to their potential damage to patients who may potentially abuse them and potentially develop an addiction. Continue reading
Opioid Prescriptions Without Medical Basis– by Gigen Mammoser – Sept 2018
A new study has found that, in a startling number of visits to a physician between 2006 and 2015 when an opioid was prescribed — nearly 30 percent — there was no recorded indication for pain.
The study, published this month in the Annals of Internal Medicine, highlights a potential administrative problem among physicians who prescribe opioids, and a need for better documentation practices
What did the study find?
In the study, opioids were found to be prescribed in 31,943 visits, of which only 5 percent documented a cancer-related pain diagnosis. Continue reading
MedWatch Voluntary Reporting Form – for reporting adverse drug effects to the FDA
Perhaps the FDA doesn’t know how ineffective “alternative” non-opioid drugs are for pain because no one has told them. You can download a form from this site (link above) to report your experiences.
Use the MedWatch form to report adverse events that you observe or suspect for human medical products,including
- serious drug side effects,
- product use/medication error,
- product quality problems, and
- therapeutic failures
It’s this last category that presents our opportunity for action. We could report the “therapeutic failures” and awful side-effects of non-opioid medicaitons like Lyrica, gabapentin, or antidepressants for pain. Continue reading
Anticonvulsants May Be Ineffective for Low Back, Lumbar Radicular Pain – Hannah Dellabella – Sept 2018
Many pain patients cut off from the relief opioids provided turn to prescriptions of these “maybe they’ll work, but they probably won’t” non-opioid drugs in desperation for some relief of their intractable pain.
From what I’ve heard, these drugs have serious cognitive side effects (memory, concentration) and are usually not effective. I use Lyrica to tamp down the spread of pain flares, but it has zero effect on my usual nociceptive pain from EDS.
For this systematic review, investigators searched 5 databases from studies examining the effects of an anticonvulsant compared with placebo in participants with nonspecific low back pain, sciatica, or neurogenic claudication of any duration. Continue reading
FDA Investigating Misuse, Abuse of Gabapentinoids – by Joyce Frieden, News Editor, MedPage Today – February 15, 2018
Gabapentinoids such as pregabalin (Lyrica) as well as the original agent gabapentin (Neurontin) are approved to treat a variety of conditions, including post-herpetic neuralgia, fibromyalgia, and neuropathic pain associated with diabetes, and
“some literature suggests that clinicians may be prescribing these drugs off-label … as alternatives to opioids, outside approved indications,” Gottlieb said.
Desperate times call for desperate measures. Continue reading
Study Shows How Aspirin Fights Inflammation – National Pain Report
A daily low-dose aspirin has long been recommended by doctors for its cardiovascular benefits.
But only now are researchers getting a better understanding of how aspirin reduces the inflammation that can lead to heart disease and other chronic health conditions.
So, doctors were recommending something even though they didn’t know its mechanism of action. I always thought it worked because it thinned the blood. Continue reading